Acasti Pharma Inc.

0.4711-0.0389-7.63%Vol 10.35M1Y Perf 8.59%
Apr 13th, 2021 16:00 DELAYED
BID0.4625 ASK0.4650
Open0.5029 Previous Close0.5100
Pre-Market- After-Market0.47
 - -  -0.01 -1.27%
Target Price
0.15 
Analyst Rating
Moderate Buy 1.75
Potential %
-68.16 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
+ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap84.56M 
Earnings Rating
Buy
Price Range Ratio 52W %
28.61 
Earnings Date
12th Feb 2021

Today's Price Range

0.45100.5039

52W Range

0.17101.22

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-10.53%
1 Month
-29.56%
3 Months
-20.25%
6 Months
135.02%
1 Year
8.59%
3 Years
-53.64%
5 Years
-62.77%
10 Years
-

TickerPriceChg.Chg.%
ACST0.4711-0.0389-7.63
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Earnings HistoryEstimateReportedSurprise %
Q03 2021--0.02-
Q02 2021-0.07-0.0528.57
Q01 2021-0.07-0.0528.57
Q04 2020-0.09-0.0544.44
Q03 2020-0.13-0.14-7.69
Q02 2020-0.08-0.080.00
Q01 2020-0.12-0.118.33
Q04 2019-0.11-0.17-54.55
Earnings Per EndEstimateRevision %Trend
12/2020 QR-0.07-16.67Negative
3/2021 QR0.00100.00Positive
3/2021 FY-0.195.00Positive
3/2022 FY-0.180.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume10.35M
Shares Outstanding179.50M
Trades Count19.09K
Dollar Volume12.48M
Avg. Volume38.89M
Avg. Weekly Volume8.81M
Avg. Monthly Volume10.35M
Avg. Quarterly Volume30.16M

Acasti Pharma Inc. (NASDAQ: ACST) stock closed at 0.51 per share at the end of the most recent trading day (a -5.35% change compared to the prior day closing price) with a volume of 6.70M shares and market capitalization of 84.56M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 32 people. Acasti Pharma Inc. CEO is Janelle D'Alvise.

The one-year performance of Acasti Pharma Inc. stock is 8.59%, while year-to-date (YTD) performance is 56.92%. ACST stock has a five-year performance of -62.77%. Its 52-week range is between 0.171 and 1.22, which gives ACST stock a 52-week price range ratio of 28.61%

Acasti Pharma Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 58.49, a price-to-sale (PS) ratio of 602.07, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of 7.11%, a ROC of 22.35% and a ROE of 27.21%. The company’s profit margin is -%, its EBITDA margin is 5 140.70%, and its revenue ttm is $82.08 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Acasti Pharma Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Acasti Pharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Acasti Pharma Inc. is Moderate Buy (1.75), with a target price of $0.15, which is -68.16% compared to the current price. The earnings rating for Acasti Pharma Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Acasti Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Acasti Pharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 27.69, ATR14 : 0.11, CCI20 : -127.10, Chaikin Money Flow : -0.24, MACD : -0.05, Money Flow Index : 27.95, ROC : -15.24, RSI : 44.66, STOCH (14,3) : 4.36, STOCH RSI : 0.81, UO : 34.38, Williams %R : -95.64), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Acasti Pharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (50.00 %)
3 (60.00 %)
2 (50.00 %)
Moderate Buy
1 (25.00 %)
1 (20.00 %)
1 (25.00 %)
Hold
1 (25.00 %)
1 (20.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.75
Moderate Buy
1.60
Moderate Buy
1.75

Acasti Pharma Inc.

Acasti Pharma Inc is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company is focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the blood lipids associated with cardiovascular disease risk. The Company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia.

CEO: Janelle D'Alvise

Telephone: +1 438 399-7114

Address: 545, Promenade du Centropolis, Laval H7T 0A3, QC, CA

Number of employees: 32

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

59%41%

News

Stocktwits